We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Markers Linked to Development of Lymphedema

By LabMedica International staff writers
Posted on 08 May 2013
Print article
Image: Bioimpedance spectroscopy device (Photo courtesy of ImpediMed).
Image: Bioimpedance spectroscopy device (Photo courtesy of ImpediMed).
A clear association has been revealed between certain genes and the development of lymphedema, after breast cancer surgery and certain other cancer treatments.

The risks of developing lymphedema increases significantly for women who had more advanced breast cancer at the time of diagnosis, more lymph nodes removed or a significantly higher body mass index.

Scientists at the University of California - San Francisco (CA, USA) investigated 410 women who were at least six months post-treatment for breast cancer surgery on one breast, and either had lymphedema in their upper extremity or did not have the condition.

The team evaluated genetic predictors of lymphedema using a type of technology called bioimpedance spectroscopy (BIS) to measure increases in fluid in the arm. Bioimpedance spectroscopy is a noninvasive procedure that allows one to measure body composition including an increase in fluid in an arm or a leg. Genotyping was done using a custom genotyping array.

The BIS measurements were taken using a single channel BIS device (SFB7 device; ImpediMed; San Diego, CA; USA) in the lymphedema study or the Quantum X Bioelectrical Impedance Device (RJL Systems; Clinton Township, MI, USA) in another study. Genotyping was performed blinded to lymphedema status and positive and negative controls were included. DNA was quantitated with a Nanodrop Spectrophotometer (Wilmington, DE, USA). Samples were genotyped using the GoldenGate genotyping platform (Illumina; San Diego, CA, USA).

The scientist found that while not all of the candidate genes were associated with the development of LE, the significant associations that were identified provide new information on genomic risk factors and potential therapeutic targets. They found that women with lymphedema had more advanced breast cancer at the time of diagnosis; a higher number of positive lymph nodes; and were more likely to have a significantly higher body mass index.

Christine Miaskowski, RN, PhD, the lead author, said, “These findings suggest that complex interactions may exist between a variety of patient characteristics and genetic markers that place some women at higher risk for the development of lymphedema. Our hope is that once our findings are confirmed in a future study, we will be able to identify women at higher risk for lymphedema prior to breast cancer surgery, and initiate measures to prevent the development of this devastating condition." The study was published on April 16, 2013, in the journal Public Library of Science ONE.

Related Links:

University of California - San Francisco
ImpediMed
RJL Systems


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.